HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yan, J.-H. Articles by Orringer, E. Search for Related Content PubMed PubMed Citation Articles by Yan, J.-H. Articles by Orringer, E. Social Bookmarking                   What's this?

The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease

From Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey (Dr Yan, Dr Kaul, Dr Grasela); University of North Carolina, Chapel Hill, North Carolina (Dr Ataga, Dr Orringer); Bristol-Myers Squibb Pharmaceutical Research Institute, Plainsboro, New Jersey (Dr Olson, Dr Gothelf); and Medical College of Georgia, Augusta, Georgia (Dr Kutlar).

This was an open-label, nonrandomized, 2-center study conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea in adults with sickle cell disease (SCD). Seventeen patients were divided into 5 groups: normal renal function (n = 7), mild renal impairment (n = 2), moderate renal impairment (n = 3), severe renal impairment (n = 2), and end-stage renal disease (ESRD, n = 3). Except for patients with ESRD, all the patients received a 15-mg/kg single oral dose of hydroxyurea. Patients with ESRD received a 15-mg/kg oral dose of hydroxyurea on 2 occasions. Blood and urine samples were collected for the assessment of hydroxyurea pharmacokinetics. The results indicate that the systemic exposure increases and the urinary recovery decreases as the degree of renal insufficiency worsens. On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7.5 mg/kg/day) for SCD patients with CL_cr <60 mL/min. This dosing strategy is anticipated to provide a safe dose for SCD patients with renal impairment.

Key Words: Hydroxyurea • sickle cell disease • renal function

Address for reprints: Jing-He Yan, PhD, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				O. S. Platt Hydroxyurea for the Treatment of Sickle Cell Anemia N. Engl. J. Med., March 27, 2008; 358(13): 1362 - 1369. [Full Text] [PDF]

				A. H. Piersma, G. Janer, G. Wolterink, J. G. M. Bessems, B. C. Hakkert, and W. Slob Quantitative Extrapolation of In Vitro Whole Embryo Culture Embryotoxicity Data to Developmental Toxicity In Vivo Using the Benchmark Dose Approach Toxicol. Sci., January 1, 2008; 101(1): 91 - 100. [Abstract] [Full Text] [PDF]

				L. Markasz, G. Stuber, B. Vanherberghen, E. Flaberg, E. Olah, E. Carbone, S. Eksborg, E. Klein, H. Skribek, and L. Szekely Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells Mol. Cancer Ther., February 1, 2007; 6(2): 644 - 654. [Abstract] [Full Text] [PDF]

				D. A. Reardon, M. J. Egorin, J. A. Quinn, J. N. Rich Sr, I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J. M. Provenzale, J. E. Herndon II, et al. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme J. Clin. Oncol., December 20, 2005; 23(36): 9359 - 9368. [Abstract] [Full Text] [PDF]